Pusan National University Yangsan Hospital
Yangsan, Gyeungsangnam-do, 50612, South Korea
NCT Number: NCT03849378
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Sargassum Horneri Extract in patients with skin hypersensitivity for 12 weeks.
Looking for future studies?
Notify Me12 year–50 year
All sexes
Interventional
Not applicable
Yangsan, Gyeungsangnam-do, 50612, South Korea
Previous studies have indicated that Panax Ginseng C.A. Mey Extract may have the ability to improve liver function. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the Sargassum Horneri Extract in patients with skin hypersensitivity for 12 weeks; the safety of the compound are also evaluate. The Investigators examine SCORAD(SCORing of Atopic Dermatitis) score, PGA (Patient Global assessment) score, IGA (Investigator Global assessment) score, total IgE, eosinophil counts, ECP, IL-4, IL-31, and TARC at baseline, as well as after 6 and 12 weeks of intervention. One hundred adults were administered either 1,000 mg of Sargassum Horneri Extract or a placebo each day for 12 weeks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
Time frame: Change from Baseline SCORAD total score at 3 months
Change in SCORAD total score during 3 months
Time frame: Change from Baseline PGA score at 3 months
Change in PGA score during 3 months
Time frame: Change from Baseline IGA score at 3 months
Change in IGA score during 3 months
Time frame: Change from Baseline total IgE (IU/mL) level at 3 months
Change in total IgE (IU/mL) level during 3 months
Time frame: Change from Baseline eosinophil counts (/uL) at 3 months
Change in eosinophil counts (/uL) during 3 months
Time frame: Change from Baseline ECP (μg/L) level at 3 months
Change in ECP (μg/L) level during 3 months
Time frame: Change from Baseline IL-4 (ng/mL) level at 3 months
Change in IL-4 (ng/mL) level during 3 months
Time frame: Change from Baseline IL-31 (ng/mL) level at 3 months
Change in IL-31 (ng/mL) level during 3 months
Time frame: Change from Baseline TARC (pg/mL) level at 3 months
Change in TARC (pg/mL) level during 3 months
Pusan National University Yangsan Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.